Relationship between postoperative tumor recurrence time and long-term survival in colorectal cancer patients

Table 3 Comparison of post-operative adjuvant treatment between groups, n (%)

Treatment parameters	Early recurrence group (n = 63)	Late recurrence group (n = 57)	Statistical value	P value
Received adjuvant chemotherapy			χ² = 0.033	0.856
Yes	58 (92.1)	53 (93.0)
No	5 (7.9)	4 (7.0)
Chemotherapy regimen	n = 58	n = 53	χ² = 0.215	0.643
FOLFOX	36 (62.1)	31 (58.5)
XELOX	22 (37.9)	22 (41.5)
Chemotherapy cycles (mean ± SD)	6.7 ± 1.6	6.9 ± 1.5	t = 0.723	0.471
Completed standard chemotherapy	n = 63	n = 57	χ² = 0.300	0.584
Yes (6-8 cycles)	46 (73.0)	44 (77.2)
No (< 6 cycles)	17 (27.0)	13 (22.8)
Chemotherapy adverse reactions	n = 58	n = 53	χ² = 0.158	0.691
≥ Grade 3	14 (24.1)	11 (20.8)
< Grade 3	44 (75.9)	42 (79.2)
Neoadjuvant chemoradiotherapy for RC	n = 27	n = 22	χ² = 0.000	0.988
Received	11 (40.7)	9 (40.9)
Not received	16 (59.3)	13 (59.1)
Post-operative radiotherapy for RC	n = 27	n = 22	χ² = 0.074	0.785
Received	9 (33.3)	8 (36.4)
Not received	18 (66.7)	14 (63.6)
Surgical approach			χ² = 0.186	0.666
Open surgery	37 (58.7)	31 (54.4)
Laparoscopic surgery	26 (41.3)	26 (45.6)

Denominators for chemotherapy regimen and adverse reactions are patients receiving adjuvant chemotherapy. Denominators for rectal cancer-related treatments are rectal cancer patients (27 in early recurrence group, 22 in late recurrence group). FOLFOX: Oxaliplatin + leucovorin + 5-fluorouracil; XELOX: Oxaliplatin + capecitabine; RC: Rectal cancer.